Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Cash & Equivalents (2023 - 2025)

Upstream Bio has reported Cash & Equivalents over the past 3 years, most recently at $101.6 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $101.6 million for Q4 2025, down 68.36% from a year ago — trailing twelve months through Dec 2025 was $101.6 million (down 68.36% YoY), and the annual figure for FY2025 was $101.6 million, down 68.36%.
  • Cash & Equivalents for Q4 2025 was $101.6 million at Upstream Bio, up from $72.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for UPB hit a ceiling of $321.0 million in Q4 2024 and a floor of $23.3 million in Q4 2023.
  • Median Cash & Equivalents over the past 3 years was $47.3 million (2023), compared with a mean of $79.4 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 1277.68% in 2024 and later plummeted 68.36% in 2025.
  • Upstream Bio's Cash & Equivalents stood at $23.3 million in 2023, then skyrocketed by 1277.68% to $321.0 million in 2024, then plummeted by 68.36% to $101.6 million in 2025.
  • The last three reported values for Cash & Equivalents were $101.6 million (Q4 2025), $72.2 million (Q3 2025), and $45.5 million (Q2 2025) per Business Quant data.